Recent Post
Related Posts
Key Insights into Pharmacokinetics: How Drugs “Know Where to Act” and Their Journey Through the Body
By: Diego A. Rodríguez Soacha BPharm, MSc, Dr. rer. Nat. Senior Medicinal Chemist The journey of drugs within the body underscores pharmacokinetics as a cornerstone of effective drug development. By
By: Saadia Shahnawaz, MD Medical Director Research has shown a complex interaction between the Endocannabinoid System (ECS) and the immune system, emphasizing the ECS’s role in regulating immune responses and
Raising the Voice: A Comment on Race and Ethnic Disparities in Alzheimer’s Disease Clinical Research
Alzheimer’s Disease clinical research has faced a significant challenge for a long time in achieving diverse racial or ethnic representation in clinical trials. Many of these issues are rooted in
Hypertension as a Risk Factor for Cognitive Decline
Hypertension, or high blood pressure, significantly impacts public health worldwide. Hypertension is well recognized for its role in cardiovascular disease, revealing implications for cognitive decline and dementia. Increasing clinical evidence
IGC PHARMA Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively.
Subscribe to get our latest content by email.
